Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-20-000159
Filing Date
2020-02-27
Accepted
2020-02-27 17:14:42
Documents
2
Group Members
ARUN KUMAR PILLAIGHIATH M. SUKHTIANGMS VENTURES & INVESTMENTS

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 11 ss167367_sc13da.htm SC 13D/A 127984
2 JOINT FILING AGREEMENT ss167367_ex9901.htm EX-99.1 6882
  Complete submission text file 0000947871-20-000159.txt   136590
Mailing Address 7 CLARKE DRIVE CRANBURY NJ 08512
Business Address 7 CLARKE DRIVE CRANBURY NJ 08512 6096193990
Outlook Therapeutics, Inc. (Subject) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: SC 13D/A | Act: 34 | File No.: 005-89495 | Film No.: 20663736
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 36 ROBINSON ROAD, #13-01 CITY HOUSE SINGAPORE U0 068877
Business Address 36 ROBINSON ROAD, #13-01 CITY HOUSE SINGAPORE U0 068877 962 6 582 7999
BioLexis Pte Ltd. (Filed by) CIK: 0001716335 (see all company filings)

EIN.: 000000000
Type: SC 13D/A